{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T17:39:17Z","timestamp":1774028357994,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T00:00:00Z","timestamp":1669161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T00:00:00Z","timestamp":1669161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"G. Pohl-Boskamp GmbH & Co. KG, Hohenlockstedt, Germany"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Urinary tract infections are among the most common indications for antibiotic therapy. The emergence of resistant uropathogens indicates the need for treatment alternatives. Replenishment of the glycosaminoglycan layer of the bladder, achieved by intravesical instillation of e.g. chondroitin sulphate (CS), is described to be a cornerstone in the therapy of cystitis. To retrospectively evaluate the efficacy of a therapy with 0.2% CS in patients suffering recurrent urinary tract infections (rUTI) in comparison to a treatment with low-dose long-term antibiotics (LDLTAB) and a combination of both.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A total of 151 patients with recurrent UTI who underwent intravesical therapy at Diaconesse hospital in Leiden, The Netherlands were included. 50 patients had been treated with CS, 51 patients had received LDLTAB, and 50 patients had received a combination therapy (LDLTABCS). Data recorded for baseline, after 6, and 12\u00a0months of treatment were evaluated. Descriptive statistics were calculated. Exploratory comparisons between groups and within groups were performed by using one-tailed and paired t-tests. Patients filled in a standardized quality of life questionnaire (EQ-5D).\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We found a statistically significant reduction of number of infections from 7.10\u2009\u00b1\u20090.50 SEM to 0.45\u2009\u00b1\u20090.07 SEM after 12\u00a0months therapy with CS compared to 12\u00a0months therapy with LDLTAB (from 7.04\u2009\u00b1\u20090.47 SEM to 1.8\u2009\u00b1\u20090.15 SEM). The number of visits to the urologist significantly decreased in the CS group from 7.46\u2009\u00b1\u20090.80 SEM to 1.28\u2009\u00b1\u20090.11 SEM and from 4.10\u2009\u00b1\u20090.29 SEM to 1.35\u2009\u00b1\u20090.11 SEM in the LDLTABCS group. In addition, a significant increase in Quality of life (QoL) was seen in the CS-group (from 58.2\u2009\u00b1\u20090.82 SEM to 80.43\u2009\u00b1\u20090.82 SEM) and in the LDLTABCS group (from 62.4\u2009\u00b1\u20090.97 SEM to 76.73\u2009\u00b1\u20091.06 SEM). There was no improvement in QoL with LDLTAB (from 58.24\u2009\u00b1\u20091.08 SEM to 58.96\u2009\u00b1\u20091.19 SEM). Evaluation\u2019s evidence is limited due to its retrospective character.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Retrospective analysis of data from patients that underwent therapy for rUTIs confirms the safety and efficacy of CS and indicate a superiority to antibiotic treatment of rUTIs.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12894-022-01149-7","type":"journal-article","created":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T18:32:04Z","timestamp":1669314724000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The efficacy and safety of intravesical chondroitin sulphate solution in recurrent urinary tract infections"],"prefix":"10.1186","volume":"22","author":[{"given":"M. S.","family":"Rahnama\u2019i","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Javan Balegh Marand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"R\u00f6schmann-Doose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Steffens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. J.","family":"Arendsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,23]]},"reference":[{"key":"1149_CR1","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/S0022-5347(01)61948-7","volume":"161","author":"PM Hanno","year":"1999","unstructured":"Hanno PM, Landis JR, Matthews-Cook Y, Kusek J. The diagnosis of interstitial cystitis revisited: lessons learned from the National Institutes of Health Interstitial Cystitis Database study. J Urol. 1999;161:553\u20137.","journal-title":"J Urol"},{"key":"1149_CR2","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s00192-010-1357-0","volume":"22","author":"MH Hazewinkel","year":"2011","unstructured":"Hazewinkel MH, Stalpers LJ, Dijkgraaf MG, Roovers J-PW. Prophylactic vesical instillations with 0.2% chondroitin sulfate may reduce symptoms of acute radiation cystitis in patients undergoing radiotherapy for gynecological malignancies. Int Urogynecol J. 2011;22:725\u201330.","journal-title":"Int Urogynecol J"},{"key":"1149_CR3","first-page":"1135","volume":"43","author":"A Loch","year":"2004","unstructured":"Loch A, Stein U. Interstitielle Zystitis. Der Urologe, Ausgabe A. 2004;43:1135\u201346.","journal-title":"Der Urologe, Ausgabe A"},{"key":"1149_CR4","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nrmicro3432","volume":"13","author":"AL Flores-Mireles","year":"2015","unstructured":"Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015;13:269\u201384.","journal-title":"Nat Rev Microbiol"},{"key":"1149_CR5","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ejogrb.2011.01.028","volume":"156","author":"S Salvatore","year":"2011","unstructured":"Salvatore S, et al. Urinary tract infections in women. Eur J Obstet Gynecol Reprod Biol. 2011;156:131\u20136.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"1149_CR6","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1007\/s10156-013-0609-6","volume":"19","author":"M Torella","year":"2013","unstructured":"Torella M, et al. Intravesical therapy in recurrent cystitis: a multi-center experience. J Infect Chemother. 2013;19:920\u20135.","journal-title":"J Infect Chemother"},{"key":"1149_CR7","doi-asserted-by":"publisher","DOI":"10.1172\/JCI158497","author":"CJ Worby","year":"2022","unstructured":"Worby CJ, Olson BS, Dodson KW, Earl AM, Hultgren SJ. Establishing the role of the gut microbiota in susceptibility to recurrent urinary tract infections. J Clin Invest. 2022. https:\/\/doi.org\/10.1172\/JCI158497.","journal-title":"J Clin Invest"},{"key":"1149_CR8","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1111\/j.1574-6976.2012.00339.x","volume":"36","author":"TJ Hannan","year":"2012","unstructured":"Hannan TJ, et al. Host\u2013pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic Escherichia coli bladder infection. FEMS Microbiol Rev. 2012;36:616\u201348.","journal-title":"FEMS Microbiol Rev"},{"key":"1149_CR9","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.juro.2012.09.022","volume":"189","author":"DA Janssen","year":"2013","unstructured":"Janssen DA, et al. The distribution and function of chondroitin sulfate and other sulfated glycosaminoglycans in the human bladder and their contribution to the protective bladder barrier. J Urol. 2013;189:336\u201342.","journal-title":"J Urol"},{"key":"1149_CR10","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1067\/mda.2003.8","volume":"49","author":"A Ronald","year":"2003","unstructured":"Ronald A. The etiology of urinary tract infection: traditional and emerging pathogens. Dis Mon. 2003;49:71\u201382.","journal-title":"Dis Mon"},{"key":"1149_CR11","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01977-19","author":"R Thanert","year":"2019","unstructured":"Thanert R, et al. Comparative genomics of antibiotic-resistant uropathogens implicates three routes for recurrence of urinary tract infections. MBio. 2019. https:\/\/doi.org\/10.1128\/mBio.01977-19.","journal-title":"MBio"},{"key":"1149_CR12","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.ajic.2014.06.013","volume":"42","author":"A Sorlozano","year":"2014","unstructured":"Sorlozano A, et al. Evolution of the resistance to antibiotics of bacteria involved in urinary tract infections: a 7-year surveillance study. Am J Infect Control. 2014;42:1033\u20138.","journal-title":"Am J Infect Control"},{"key":"1149_CR13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jgar.2018.11.004","volume":"17","author":"S Ny","year":"2019","unstructured":"Ny S, et al. Antimicrobial resistance of Escherichia coli isolates from outpatient urinary tract infections in women in six European countries including Russia. J Glob Antimicrob Resist. 2019;17:25\u201334. https:\/\/doi.org\/10.1016\/j.jgar.2018.11.004.","journal-title":"J Glob Antimicrob Resist"},{"key":"1149_CR14","unstructured":"Grabe, M. et al. Edition presented at the 28th EAU Annual Congress, Milano."},{"key":"1149_CR15","doi-asserted-by":"publisher","first-page":"e00143","DOI":"10.1128\/JCM.00143-19","volume":"57","author":"HJ Ho","year":"2019","unstructured":"Ho HJ, et al. Interaction between antibiotic resistance, resistance genes, and treatment response for urinary tract infections in primary care. J Clin Microbiol. 2019;57:e00143-e1119.","journal-title":"J Clin Microbiol"},{"key":"1149_CR16","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1016\/S0022-5347(01)63178-1","volume":"159","author":"CL Parsons","year":"1998","unstructured":"Parsons CL, Greenberger M, Gabal L, Bidair M, Barme G. The role of urinary potassium in the pathogenesis and diagnosis of interstitial cystitis. J Urol. 1998;159:1862\u20137.","journal-title":"J Urol"},{"key":"1149_CR17","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/nau.1930130503","volume":"13","author":"CL Parsons","year":"1994","unstructured":"Parsons CL, Stein PC, Bidair M, Lebow D. Abnormal sensitivity to intravesical potassium in interstitial cystitis and radiation cystitis. Neurourol Urodyn. 1994;13:515\u201320.","journal-title":"Neurourol Urodyn"},{"key":"1149_CR18","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1111\/iju.12430","volume":"21","author":"A Cicione","year":"2014","unstructured":"Cicione A, et al. Restoring the glycosaminoglycans layer in recurrent cystitis: experimental and clinical foundations. Int J Urol. 2014;21:763\u20138. https:\/\/doi.org\/10.1111\/iju.12430.","journal-title":"Int J Urol"},{"key":"1149_CR19","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1177\/1756287211418723","volume":"3","author":"R Damiano","year":"2011","unstructured":"Damiano R, Cicione A. The role of sodium hyaluronate and sodium chondroitin sulphate in the management of bladder disease. Ther Adv Urol. 2011;3:223\u201332. https:\/\/doi.org\/10.1177\/1756287211418723.","journal-title":"Ther Adv Urol"},{"key":"1149_CR20","first-page":"1199","volume":"64","author":"JF Metts","year":"2001","unstructured":"Metts JF. Interstitial cystitis: urgency and frequency syndrome. Am Fam Phys. 2001;64:1199\u2013206.","journal-title":"Am Fam Phys"},{"key":"1149_CR21","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0090-4295(00)01110-9","volume":"57","author":"CL Parsons","year":"2001","unstructured":"Parsons CL, Zupkas P, Parsons JK. Intravesical potassium sensitivity in patients with interstitial cystitis and urethral syndrome. Urology. 2001;57:428\u201332.","journal-title":"Urology"},{"key":"1149_CR22","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/S1569-9056(03)00036-8","volume":"2","author":"R Sorensen","year":"2003","unstructured":"Sorensen R. Chondroitin sulphate in the treatment of interstitial cystitis and chronic inflammatory disease of the urinary bladder. Eur Urol Suppl. 2003;2:16\u20138.","journal-title":"Eur Urol Suppl"},{"key":"1149_CR23","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/j.1464-410X.2008.08028.x","volume":"103","author":"J Nickel","year":"2009","unstructured":"Nickel J, et al. A real-life multicentre clinical practice study to evaluate the efficacy and safety of intravesical chondroitin sulphate for the treatment of interstitial cystitis. BJU Int. 2009;103:56\u201360.","journal-title":"BJU Int"},{"key":"1149_CR24","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1590\/s1677-5538.ibju.2016.0302","volume":"43","author":"M Tutolo","year":"2017","unstructured":"Tutolo M, et al. A prospective randomized controlled multicentre trial comparing intravesical DMSO and chondroitin sulphate 2% for painful bladder syndrome\/interstitial cystitis. Int Braz J Urol. 2017;43:134\u201341.","journal-title":"Int Braz J Urol"},{"key":"1149_CR25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/nau.22256","volume":"32","author":"H Madersbacher","year":"2013","unstructured":"Madersbacher H, van Ophoven A, van Kerrebroeck PE. GAG layer replenishment therapy for chronic forms of cystitis with intravesical glycosaminoglycans\u2014a review. Neurourol Urodyn. 2013;32:9\u201318.","journal-title":"Neurourol Urodyn"},{"key":"1149_CR26","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1055\/s-2008-1039143","volume":"68","author":"A Gauruder-Burmester","year":"2009","unstructured":"Gauruder-Burmester A, Popken G. Zwei-Jahres-follow-up nach Einsatz von Natrium-Chondroitinsulfat bei der Behandlung der \u201e\u00dcberaktiven Blase \u201c. Geburtshilfe Frauenheilkd. 2009;68:1077\u201381.","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"1149_CR27","first-page":"328","volume":"58","author":"J Nordling","year":"2007","unstructured":"Nordling J, van Ophoven A. Intravesical glycosaminoglycan replenishment with chondroitin sulphate in chronic forms of cystitis. A multi-national, multi-centre, prospective observational clinical trial. Arzneimittelforschung. 2007;58:328\u201335.","journal-title":"Arzneimittelforschung"},{"key":"1149_CR28","unstructured":"Grabe, M. et al. Guidelines on urological infections. Eur Assoc Urol 79 (2010)."},{"key":"1149_CR29","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S0924-8579(00)00359-9","volume":"17","author":"JW Warren","year":"2001","unstructured":"Warren JW. Catheter-associated urinary tract infections. Int J Antimicrob Agents. 2001;17:299\u2013303.","journal-title":"Int J Antimicrob Agents"},{"key":"1149_CR30","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1111\/j.1464-410X.2004.04850.x","volume":"93","author":"C Constantinides","year":"2004","unstructured":"Constantinides C, et al. Prevention of recurrent bacterial cystitis by intravesical administration of hyaluronic acid: a pilot study. BJU Int. 2004;93:1262\u20136.","journal-title":"BJU Int"},{"key":"1149_CR31","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.eururo.2010.12.039","volume":"59","author":"R Damiano","year":"2011","unstructured":"Damiano R, et al. Prevention of recurrent urinary tract infections by intravesical administration of hyaluronic acid and chondroitin sulphate: a placebo-controlled randomised trial. Eur Urol. 2011;59:645\u201351.","journal-title":"Eur Urol"},{"key":"1149_CR32","doi-asserted-by":"publisher","DOI":"10.1007\/s00192-012-1794-z","author":"D De Vita","year":"2012","unstructured":"De Vita D, Giordano S. Effectiveness of intravesical hyaluronic acid\/chondroitin sulfate in recurrent bacterial cystitis: a randomized study. Int Urogynecol J. 2012. https:\/\/doi.org\/10.1007\/s00192-012-1794-z.","journal-title":"Int Urogynecol J"},{"key":"1149_CR33","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ijgo.2006.11.025","volume":"96","author":"M Lipovac","year":"2007","unstructured":"Lipovac M, et al. Prevention of recurrent bacterial urinary tract infections by intravesical instillation of hyaluronic acid. Int J Gynecol Obstet. 2007;96:192\u20135.","journal-title":"Int J Gynecol Obstet"},{"key":"1149_CR34","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/s00192-011-1546-5","volume":"23","author":"D Porru","year":"2012","unstructured":"Porru D, et al. Impact of intravesical hyaluronic acid and chondroitin sulfate on bladder pain syndrome\/interstitial cystitis. Int Urogynecol J. 2012;23:1193\u20139.","journal-title":"Int Urogynecol J"},{"key":"1149_CR35","doi-asserted-by":"publisher","first-page":"e00356","DOI":"10.1128\/mBio.00356-15","volume":"6","author":"LW Goneau","year":"2015","unstructured":"Goneau LW, et al. Subinhibitory antibiotic therapy alters recurrent urinary tract infection pathogenesis through modulation of bacterial virulence and host immunity. MBio. 2015;6:e00356-e1315.","journal-title":"MBio"},{"key":"1149_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2334-13-19","volume":"13","author":"I Linhares","year":"2013","unstructured":"Linhares I, Raposo T, Rodrigues A, Almeida A. Frequency and antimicrobial resistance patterns of bacteria implicated in community urinary tract infections: a ten-year surveillance study (2000\u20132009). BMC Infect Dis. 2013;13:1\u201314.","journal-title":"BMC Infect Dis"},{"key":"1149_CR37","unstructured":"Grabe, M et al. Guidelines on urological infections. Euro Assoc Urol. 2015;182:237\u201357."},{"key":"1149_CR38","doi-asserted-by":"publisher","first-page":"224","DOI":"10.12891\/ceog4571.2018","volume":"45","author":"D De Vita","year":"2018","unstructured":"De Vita D, et al. Long-term efficacy of intravesical instillation of hyaluronic acid\/chondroitin sulfate in recurrent bacterial cystitis: 36 months\u2019 follow-up. Clin Exp Obstet Gynecol. 2018;45:224\u20138.","journal-title":"Clin Exp Obstet Gynecol"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-022-01149-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-022-01149-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-022-01149-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T18:35:48Z","timestamp":1669314948000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-022-01149-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,23]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1149"],"URL":"https:\/\/doi.org\/10.1186\/s12894-022-01149-7","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,23]]},"assertion":[{"value":"15 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective data analysis has been approved by the Ethics Committee at Alrijne Ziekenhuis Leiden, in accordance with the provisions of the Declaration of Helsinki. Patients were asked, whether they would agree to evaluation and publication of data obtained during their treatment for research purpose and gave informed consent electronically.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"M.S. Rahnama\u2019i reports fees from Farco Pharma and G. Pohl-Boskamp. K. R\u00f6schmann-Doose is an employee of G. Pohl-Boskamp. L. Steffens is an employee of G. Pohl-Boskamp. A. Javan Balegh Marand reports no conflicts of interest. H.J. Arendsen reports fees from G. Pohl-Boskamp during the conduct of the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"188"}}